Vaxart to Present at the JMP Securities Life Sciences Private Company Conference on Friday, October 17, 2014
Vaxart’s Tablet Vaccine for H1N1 Influenza Generates Protective Immunity Equivalent to Injectable in Phase I Clinical Study